Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal

• Kohei Shitara,
• Yasuko Tada,
• Hiroyoshi Nishikawa,
• Daisuke Sugiyama,
• Sho Isoyama,
• Shigeyuki Mori,
• Yasuhiro Kojima,
• Kunihiko Hinohara,
• Shingo Dan

Affiliations

Kohei Shitara

Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan

Yasuko Tada

Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Tokyo/Kashiwa, Japan

Hiroyoshi Nishikawa

Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Chuo-ku/Kashiwa, Japan

Daisuke Sugiyama

Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Sho Isoyama

Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Tokyo/Kashiwa, Japan

Shigeyuki Mori

Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Tokyo/Kashiwa, Japan

Yasuhiro Kojima

Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Kunihiko Hinohara

Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Shingo Dan

Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan